Home/ Stocks/ CSTL

Castle Biosciences, Inc. Common Stock

CSTL XNAS

$19.83 +0.59 (+3.07%) ▲ 15-min delayed

Open

$19.26

High

$19.85

Low

$18.66

Volume

498.5K

Market Cap

$601.44M

About Castle Biosciences, Inc. Common Stock

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.

Sector: SERVICES-MEDICAL LABORATORIES Employees: 942 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$83.68M	$-14,522,000	$-0.49
FY 2025	$344.23M	$-24,158,000	$-0.83
Q3 2025	$83.04M	$-501,000	$-0.02
Q2 2025	$86.19M	$4.52M	$0.16

Earnings & Analyst Ratings

Next Earnings: Mon, Aug 3, 2026

Calendar →

Related Market News

No specific coverage for CSTL yet. Check out our latest market news or earnings calendar.

Get CSTL Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Castle Biosciences, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.